Revalesio Corporation — Biomedical Watch V2

Traitements4programmes

Essais1liés

Publications3liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Interferon beta 1aThe purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.	SEP	Phase 2	À vérifier	United States	À vérifier
RNS60 125 mlThe purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.	SEP	Phase 2	À vérifier	United States	À vérifier
RNS60 250 mlThe purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.	SEP	Phase 2	À vérifier	United States	À vérifier
RNS60 125 mlThe purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.	SEP	Phase 2	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
RNS60 125 ml	SEP	Phase 2	NCT01714089	Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis	WITHDRAWN

Publications

3

Molécule	Indication / population	Titre	Journal	Date
Interferon beta 1a		Rule-based semi-automated method to segment black hole multiple sclerosis lesions on post-gadolinium 2D T1-weighted brain images.	European radiology
Interferon beta 1a		Dynamics of Myelin-Specific T-Cell Repertoires Mirror Disease Activity and Central Nervous System Trafficking in Multiple Sclerosis.	International journal of molecular sciences
Interferon beta 1a		Urinary tract infections, urosepsis, and multiple sclerosis disease modifying therapies: a disproportionality analysis of the FDA Adverse Event Reporting System.	Multiple sclerosis and related disorders